Drugs最新文献_第5页

Correction: Elafibranor: First Approval. 更正：Elafibranor：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-09-06 DOI: 10.1007/s40265-024-02088-3

Hannah A Blair

引用次数: 0

Imetelstat: First Approval. 伊美司他首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-20 DOI: 10.1007/s40265-024-02080-x

Susan J Keam

引用次数: 0

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. 流感疫苗的有效性和普及流感疫苗的进展。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI: 10.1007/s40265-024-02083-8

Benjamin J Cowling, George N Okoli

{"title":"Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.","authors":"Benjamin J Cowling, George N Okoli","doi":"10.1007/s40265-024-02083-8","DOIUrl":"10.1007/s40265-024-02083-8","url":null,"abstract":"At various times in recent decades, surges have occurred in optimism about the potential for universal influenza vaccines that provide strong, broad, and long-lasting protection and could substantially reduce the disease burden associated with seasonal influenza epidemics as well as the threat posed by pandemic influenza. Each year more than 500 million doses of seasonal influenza vaccine are administered around the world, with most doses being egg-grown inactivated subunit or split-virion vaccines. These vaccines tend to have moderate effectiveness against medically attended influenza for influenza A(H1N1) and influenza B, and somewhat lower for influenza A(H3N2) where differences between vaccine strains and circulating strains can occur more frequently due to antigenic drift and egg adaptations in the vaccine strains. Several enhanced influenza vaccine platforms have been developed including cell-grown antigen, the inclusion of adjuvants, or higher antigen doses, to improve immunogenicity and protection. During the COVID-19 pandemic there was unprecedented speed in development and roll-out of relatively new vaccine platforms, including mRNA vaccines and viral vector vaccines. These new platforms present opportunities to improve protection for influenza beyond existing products. Other approaches continue to be explored. Incremental improvements in influenza vaccine performance should be achievable in the short to medium term.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1013-1023"},"PeriodicalIF":13.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ivonescimab: First Approval. Ivonescimab：首次获批。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.1007/s40265-024-02073-w

Sohita Dhillon

引用次数: 0

Ensifentrine: First Approval. 安眠酮首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1007/s40265-024-02081-w

Susan J Keam

引用次数: 0

Drug-Induced Pigmentation: A Review. 药物诱发的色素沉着：综述。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI: 10.1007/s40265-024-02062-z

Aaron Tisack, Tasneem F Mohammad

{"title":"Drug-Induced Pigmentation: A Review.","authors":"Aaron Tisack, Tasneem F Mohammad","doi":"10.1007/s40265-024-02062-z","DOIUrl":"10.1007/s40265-024-02062-z","url":null,"abstract":"Drug-induced pigmentation (DIP) is estimated to account for 20% of all cases of acquired hyperpigmentation. Over 50 agents have been implicated, including antibiotics, antimalarials, antiretrovirals, antipsychotics, prostaglandin analogs, heavy metals, and chemotherapeutic agents. The skin, mucosal surfaces, nails, and hair can all be affected, with the color, distribution, onset, and duration of pigmentation varying between offending agents. Both a thorough physical examination and medication history are necessary to determine the offending agent. In terms of mechanism, DIP occurs most frequently through the accumulation of melanin within the dermis but also by drug accumulation, pigment synthesis, and iron deposition. Photoprotection, including applying a broad-spectrum sunscreen, wearing photoprotective clothing, and seeking shade, plays an important role in the prevention of exacerbation of DIP. Multiple lasers, including the picosecond alexandrite, Q-switched Nd:YAG, Q-switched alexandrite, and Q-switched ruby lasers, have been successful in obtaining clearance of DIP. In this review, we examine the unique characteristics of each of the inciting agents in terms of incidence, clinical presentation, time to onset and resolution, and pathogenesis.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1071-1091"},"PeriodicalIF":13.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. PARP 抑制剂与雄激素受体通路抑制剂联合用于转移性抗药性前列腺癌。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.1007/s40265-024-02071-y

Louise Kostos, Ben Tran, Arun A Azad

{"title":"Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.","authors":"Louise Kostos, Ben Tran, Arun A Azad","doi":"10.1007/s40265-024-02071-y","DOIUrl":"10.1007/s40265-024-02071-y","url":null,"abstract":"Despite recent advances in the treatment of metastatic prostate cancer, progression to a castration-resistant state remains inevitable for most and prognosis is limited. Genetic testing for homologous recombination repair pathway alterations is recommended for all patients with advanced prostate cancer given that a mutation is present in up to 25% of cases. Poly(ADP-ribose) polymerase (PARPis) are now approved for use in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor pathway inhibitor (ARPI) and harbour a germline or somatic homologous recombination repair mutation. Preclinical data support a synergistic effect with an ARPI and PARPi, and various ARPI-PARPi combinations have therefore been explored in phase III clinical trials. Despite heterogeneous findings, a clear hierarchy of benefit is evident, with patients harbouring a BRCA mutation deriving the greatest magnitude of benefit, followed by any homologous recombination repair mutation. The benefit in homologous recombination repair-proficient cohort is less clear, and questions remain about whether ARPI-PARPi combination therapy should be offered to patients without a homologous recombination repair mutation. With ARPIs now considered standard-of-care for metastatic hormone-sensitive prostate cancer, ARPI-PARPi combination therapy is currently being explored earlier in the treatment paradigm. The purpose of this review is to discuss the rationale behind ARPI-PARPi combination therapy, summarise the results of key clinical trials, and discuss clinical considerations and future perspectives.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1093-1109"},"PeriodicalIF":13.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of FXI Inhibitors: Hype or Hope? FXI 抑制剂的治疗潜力：炒作还是希望？

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.1007/s40265-024-02049-w

Mattia Galli, Giovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Salvatore Brugaletta, Davide Capodanno, Sebastiano Sciarretta, Dominick J Angiolillo

{"title":"Therapeutic Potential of FXI Inhibitors: Hype or Hope?","authors":"Mattia Galli, Giovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Salvatore Brugaletta, Davide Capodanno, Sebastiano Sciarretta, Dominick J Angiolillo","doi":"10.1007/s40265-024-02049-w","DOIUrl":"10.1007/s40265-024-02049-w","url":null,"abstract":"Significant advancements have shaped the landscape of anticoagulant therapy in the past two decades, including the introduction of direct oral anticoagulants (DOACs), characterized by favorable safety and efficacy profiles and reduced drug-to-drug or food interaction resulting in excellent patient compliance. However, residual concerns still exist with standard-of-care anticoagulant therapy, including the inability to use DOACs in several clinical settings and the need to further reduce the risk of bleeding. Recent improvements in the understanding of the mechanisms behind thrombus formation have led to the awareness that the intrinsic pathway of the coagulation cascade may play an important role in pathological thrombosis, but not in hemostasis. This has represented the rationale for targeting this pathway with factor XI (FXI) inhibitors, with the aim of uncoupling hemostasis and thrombosis. Clinical evidence from patients with FXI deficiency further supports this concept. A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G). To date, the majority of available trials have not gone beyond completion of phase 2 and results are conflictive making it difficult to appraise the clinical benefit of these compounds in the different clinical settings where they have been tested (i.e., atrial fibrillation, acute ischemic stroke, acute myocardial infarction, end-stage renal disease, total knee arthroplasty). Moreover, the largest phase 3 randomized trial designed to test the efficacy of asundexian over apixaban in patients with atrial fibrillation, the OCEANIC-AF, has been prematurely stopped as a result of the inferior efficacy of asundexian. In this review we discuss the pharmacological properties and available evidence generated thus far for factor XI inhibitors, providing a perspective on the current state of these drugs.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1055-1070"},"PeriodicalIF":13.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone Fragility in Diabetes and its Management: A Narrative Review. 糖尿病患者骨质脆弱及其管理：叙述性综述。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s40265-024-02078-5

David Suphadetch Leungsuwan, Manju Chandran

引用次数: 0

Elafibranor: First Approval. 伊拉布拉诺：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-09-01 Epub Date: 2024-08-07 DOI: 10.1007/s40265-024-02075-8

Hannah A Blair

引用次数: 0